A one-time opportunity to invest in Betalin
An innovative, international and unprecedented solution for diabetes
Want to take part in success?
The company is just before the start of human trials
The company has won many awards as a successful and promising startup in Pharma, including from the European Union
The company's estimated value is $51 million
Message from the CEO of Tallinn, Dr. Nikolai Konitzer
Batalin Investor Presentations Download
The number of diabetic patients in 2017, a number that is only increasing
M
0
Patients who need insulin to survive
M
0
Direct and Indirect Costs of Diabetes Treatment
T
0
$
"Logic will take you from point A to point B, Imagination will take you anywhere." Albert Einstein
Want to take part in success?
Leave your details and we will get back to you
The site is secured with SSL technology and your details are stored with us